Research programme: systemic lupus erythematosus and lupus nephritis therapeutics - EMD Serono/Massachusetts General Hospital

Drug Profile

Research programme: systemic lupus erythematosus and lupus nephritis therapeutics - EMD Serono/Massachusetts General Hospital

Latest Information Update: 18 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EMD Serono; Massachusetts General Hospital
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 03 Nov 2017 Preclinical trials in Lupus nephritis in USA (unspecified route)
  • 03 Nov 2017 Preclinical trials in Systemic lupus erythematosus in USA (unspecified route)
  • 03 Nov 2017 Pharmacodynamics data from preclinical studies in Systemic lupus erythematosus and Lupus nephritis presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top